Home22UA • FRA
add
BioNTech
Nakaraang pagsara
€101.20
Sakop ng araw
€82.75 - €105.40
Sakop ng taon
€69.70 - €124.60
Market cap
24.48B USD
Average na Volume
1.65K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.19B | -19.54% |
Gastos sa pagpapatakbo | 788.00M | 167.66% |
Net na kita | 259.50M | -43.33% |
Net profit margin | 21.81 | -29.55% |
Kita sa bawat share | 1.08 | -43.16% |
EBITDA | 278.30M | -73.22% |
Aktuwal na % ng binabayarang buwis | 13.84% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 16.78B | 1.42% |
Kabuuang asset | 22.53B | -2.07% |
Kabuuang sagutin | 3.12B | 12.98% |
Kabuuang equity | 19.41B | — |
Natitirang share | 239.97M | — |
Presyo para makapag-book | 1.25 | — |
Return on assets | 1.76% | — |
Return on capital | 2.03% | — |
Cash Flow
Net change in cash
| (EUR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 259.50M | -43.33% |
Cash mula sa mga operasyon | -463.30M | -154.45% |
Cash mula sa pag-invest | 606.70M | 122.51% |
Cash mula sa financing | -7.30M | 43.41% |
Net change in cash | 137.30M | 107.49% |
Malayang cash flow | -47.54M | -105.76% |
Tungkol
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Itinatag
2008
Website
Mga Empleyado
6,772
